Abstract:Abstract Rationale: Fabry disease (FD) is a rare, X-linked lysosomal deposition disease characterized by multi-system symptoms. The accumulation of globotriaosylceramide in various organs, such as the kidneys and heart, as well as the nervous system, has been speculated to be the mechanism involved in tissue damage, including vascular impairment with thrombotic events. Patient concerns: Here, we describe a 72-year-old male patient diagnosed with FD, who first presented with acute myocardial infarction, left ventricular thrombosis, and pericardial effusion, accompanied by cardiac hypertrophy. Diagnoses: A physical examination showed that he was hemodynamically stable and an electrocardiogram showed ventricular tachycardia (Fig. 1A). The single obvious abnormality was an ST segment depression with a preterminal negative T wave in leads I and aVL (Fig. 1B). Coronary angiography revealed regular findings (Fig. 2). Echocardiogram conducted at our hospital revealed hypertrophy, ejection fraction 40%, pericardial effusion (Fig. 3). Speckle tracking two-dimensional echocardiography strain analysis technology confirmed left ventricular thrombosis, and also revealed decreased movement of the inferior and posterior walls, the basal segment of the posterior wall was locally fibrotic (Fig. 4A and B). Further, myocardial contrast echocardiography confirmed left ventricular thrombosis (Fig. 4C). Cardiovascular magnetic resonance imaging indicated biventricular uneven hypertrophy, which was considered metabolic cardiomyopathy, with diffuse fibrosis of biventricular walls, apical thrombosis, and ischemic cardiomyopathy in the basal segment of the left ventricular lateral wall and left ventricular anterior wall (Fig. 5). Serum alpha-galactosidase concentration was 0.7 nmol/h/mgPr (normal range, 29.0–64.4 nmol/h/mgPr). Subsequent genetic testing revealed that he was hemizygous for a previously reported missense mutation (c.902G>A) inexon 6 of the GLA gene, [1] which induce p.R301Q (p.Arg301Gln), confirming a diagnosis of FD (Fig. 6). Interventions: Orally administered drugs included rivaroxaban, sacubitril valsartan, beta blockers, dapagliflozin, and mineralocorticoid receptor antagonist. Cardiac resynchronization therapy with an implanted defibrillator was implemented to prevent sudden death. Outcomes: At present, he is still in follow-up and there have been no adverse events. Conclusion: Our case suggests that clinicians should consider the possibility of FD in patients with acute myocardial infarction and cardiomyopathy. A detailed analysis of subtle historical clues would help promote earlier diagnosis of FD.

Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening

Clinical features, genetic variations and enzyme replacement therapy in five Chinese patients with Fabry disease

Clinical features and enzyme replacement therapy in 10 children with Fabry disease

Fabry Disease Presenting as End-Stage Kidney Disease

Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy

A Rare Case of Fabry's Disease-Induced Cardiomyopathy: A Case Report and Review of the Literature

Fabry Disease: Review and Experience During Newborn Screening.

Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report

Integrative Systems Biology Investigation of Fabry Disease

Clinical Observations on Enzyme Replacement Therapy in Patients with Fabry Disease and the Switch from Agalsidase Beta to Agalsidase Alfa.

Fabry disease: a rare disorder calling for personalized medicine

Fabry's disease: clinical, pathologic and biochemical manifestations in two Chinese males

Fabry Disease: Renal Biopsy-Proven Cases from China

Fabry Disease with Acute Myocardial Infarction, Left Ventricular Thrombosis, and Pericardial Effusion

[Clinical features and enzyme replacement therapy in 4 children with Fabry disease].

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis

[Clinical analysis of 10 patients with Fabry disease]

A case of female Fabry disease revealed by renal biopsy

Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic fabry disease cardiomyopathy

Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

Effectiveness and safety of enzyme replacement therapy in the treatment of Fabry disease: a Chinese monocentric real-world study